To the best of our knowledge, our results are the first to show this effect of CPA on TRAIL-induced prostate cancer cell apoptosis, and raise the possibility that a combination of TRAIL with CPA for its associated efficacy unrelated to androgen antagonism could improve treatment of CR prostate cancer. The gene discussed is TNFSF10; the disease is Familial prostate cancer.